New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia: Autophagy protection is coupled to behavioral improvements in a mouse model of schizophrenia

Avia Merenlender-Wagner 1, 2, 3 Zeev Shemer 1, 2, 3 Olga Touloumi 4 Rosa Lagoudaki 4 Eliezer Giladi 1, 2, 3 Annie Andrieux 5 Nikolaos Grigoriadis 4 Illana Gozes 1, 2, 3
1 The Adams Super Center for Brain Studies
2 The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry
3 The Lily and Avraham Gildor Chair for the Investigation of Growth Factors
4 Department of Neurology and Laboratory of Experimental Neurology
5 Equipe 1 : Physiopathologie du Cytosquelette
UJF - Université Joseph Fourier - Grenoble 1, CEA - Commissariat à l'énergie atomique et aux énergies alternatives, INSERM - Institut National de la Santé et de la Recherche Médicale : U836, [GIN] Grenoble Institut des Neurosciences
Abstract : Autophagy plays a key role in the pathophysiology of schizophrenia as manifested by a 40% decrease in BECN1/Beclin 1 mRNA in postmortem hippocampal tissues relative to controls. This decrease was coupled with the deregulation of the essential ADNP (activity-dependent neuroprotector homeobox), a binding partner of MAP1LC3B/LC3B (microtubule-associated protein 1 light chain 3 beta) another major constituent of autophagy. The drug candidate NAP (davunetide), a peptide fragment from ADNP, enhanced the ADNP-LC3B interaction. Parallel genetic studies have linked allelic variation in the gene encoding MAP6/STOP (microtubule-associated protein 6) to schizophrenia, along with altered MAP6/STOP protein expression in the schizophrenic brain and schizophrenic-like behaviors in Map6-deficient mice. In this study, for the first time, we reveal significant decreases in hippocampal Becn1 mRNA and reversal by NAP but not by the antipsychotic clozapine (CLZ) in Map6-deficient (Map6+/-) mice. Normalization of Becn1 expression by NAP was coupled with behavioral protection against hyperlocomotion and cognitive deficits measured in the object recognition test. CLZ reduced hyperlocomotion below control levels and did not significantly affect object recognition. The combination of CLZ and NAP resulted in normalized outcome behaviors. Phase II clinical studies have shown NAP-dependent augmentation of functional activities of daily living coupled with brain protection. The current studies provide a new mechanistic pathway and a novel avenue for drug development.
Type de document :
Article dans une revue
Autophagy, Taylor & Francis, 2014, 10, pp.2324 - 2332. 〈10.4161/15548627.2014.984274〉
Liste complète des métadonnées

Littérature citée [31 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-01115252
Contributeur : Annie Andrieux <>
Soumis le : mardi 10 février 2015 - 16:46:40
Dernière modification le : mardi 6 février 2018 - 01:08:39
Document(s) archivé(s) le : jeudi 28 mai 2015 - 08:35:28

Fichier

Merenlender-2014_New horizons_...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

CEA | UGA

Citation

Avia Merenlender-Wagner, Zeev Shemer, Olga Touloumi, Rosa Lagoudaki, Eliezer Giladi, et al.. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia: Autophagy protection is coupled to behavioral improvements in a mouse model of schizophrenia. Autophagy, Taylor & Francis, 2014, 10, pp.2324 - 2332. 〈10.4161/15548627.2014.984274〉. 〈inserm-01115252〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

81

Téléchargements de fichiers

1905

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD